Information Provided By:
Fly News Breaks for April 18, 2018
AIMT, DBVT
Apr 18, 2018 | 08:27 EDT
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
News For DBVT;AIMT From the Last 2 Days
There are no results for your query DBVT;AIMT